Our data confirms and extends these findings by showing that administration of IL-2/JES6-1 immunocomplexes at the time of initiating DSS treatment is sufficient to expand colonic Foxp3+ Tregs and ameliorate colitis. The gene discussed is IL2; the disease is colitis.